Back to News
Top StoriesMarketWatch3h ago
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Read Full Article on MarketWatchMENTIONED STOCKS
More Top Stories News
10-year Treasury yield briefly tops 5%, hitting its highest level since 2007 as bond-market selloff deepens
MarketWatch·2h ago
‘My total balance should be worth $20 million’: I invested $1.1 million in a crypto platform. Have I lost it all?
MarketWatch·2h ago
Couples with a big age gap need more money — they have to plan for two retirements
MarketWatch·3h ago
Here’s how to prepare your portfolio for the Fed’s next interest-rate moves
MarketWatch·3h ago
Micron, Nvidia and other chip stocks fall after tech leaders call for an AI slowdown. Here’s what to know.
MarketWatch·4h ago
Content sourced from MarketWatch. Not financial advice.